Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound Sirolimus in TSC1/2 Mutated Solid Tumors
NCT05508620Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in malignant solid tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-limiting toxicities at 21 days, Recommended phase 2 dose at 2 years and 1 more. Status: unknown.
02
Drugs
nab-sirolimus
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05508620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508620.